---
document_datetime: 2024-05-15 12:48:52
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tasigna-h-c-000798-p46-056-epar-assessment-report_en.pdf
document_name: tasigna-h-c-000798-p46-056-epar-assessment-report_en.pdf
version: success
processing_time: 21.4209136
conversion_datetime: 2025-12-27 13:13:06.390834
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
21 March 2024 EMA/167947/2024 Human Medicines Division

Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006

## Tasigna

Nilotinib

Procedure no: EMEA/H/C/000798/P46/056

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Introduction ............................................................................................3              |
|----------------------------------------------------------------------------------------------------------------------------|
| 2. Scientific discussion ................................................................................3                 |
| 2.1. Information on the development program.............................................................. 3                |
| 2.2. Information on the pharmaceutical formulation used in the study.............................. 3                       |
| 2.3. Clinical aspects .................................................................................................. 3 |
| 2.3.1. Introduction ................................................................................................... 3  |
| 2.3.2. Short description of the medicinal product .......................................................... 4             |
| 2.3.3. Study rationale, study design and study results ................................................... 4               |
| 2.3.4. Discussion on clinical aspects .......................................................................... 10        |
| 3. Overall conclusion and recommendation ...............................................11                                 |
| Annex. Line listing of all the studies included in the development program                                                 |

<div style=\"page-break-after: always\"></div>

## 1. Introduction

On 20 December 2023,the MAH submitted a completedpaediatric studyforTasigna,in accordance withArticle 46of Regulation(EC)No1901/2006,as amended.

A short critical expert overview has also been provided.

<!-- image -->

| Steps taken for the assessment            | Steps taken for the assessment   |
|-------------------------------------------|----------------------------------|
| Description                               | Actual Date                      |
| Start of procedure                        | 22 Jan 2024                      |
| CHMPRapporteur Assessment Report          | 16 Feb 2024                      |
| CHMPmemberscomments                       | n/a                              |
| Updated CHMP Rapporteur Assessment Report | n/a                              |
| CHMP adoption of conclusions:             | 21 Mar 2024                      |

## 2. Scientific discussion

## 2.1.Information on the development program

The MAH stated that study No. CAMN107A2409 (hereafter referred to as A2409) - An open label, nilotinib study and are judged by the investigator tobenefit from continued nilotinib treatment is a standalone study.

## 2.2. Information on the pharmaceutical formulation used in the study

Nilotinib was provided as 50 mg, 150 mg and 200 mg hard gelatin capsules

## 2.3. Clinical aspects

## 2.3.1. Introduction

The MAH submitted a final report for:

- CAMN107A2409(hereafter referred to as A2409)-An open label,multi-centernilotinibrolloverprotocol for patients whohave completed apreviousNovartis sponsored nilotinib study and are judged by the investigator to benefit from continued nilotinib treatment is a standalone study.

7 were pediatric patients (aged &lt;18 years) and the study concluded on 07-Jul-2023 (LPLV). This study was a voluntary post-approval safety study, but not part of a pediatric investigation plan nor postapproval commitment.

The results of this study are now submitted to the EMA, as a standalone submission, in accordance with Article 46of Regulation(EC)No 1901/2006,whichrequires submission of anyMAH-sponsored study that involves use in a pediatric population of a medicinal product covered by a marketing

<div style=\"page-break-after: always\"></div>

authorization, whether or not the study is conducted in compliance with an agreed pediatric investigation plan.

## 2.3.2. Short description of the medicinal product

Nilotinib (Tasigna®, AMN107) is a selective inhibitor of both wild-type and imatinib-resistant forms of the tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphiachromosome positive (Ph+) leukemia cells. BCR-ABL is a constitutively active tyrosine kinase and drives the pathology of chronic myelogenous leukemia, a myeloproliferative disorder characterized by a clonal expansion of hematopoietic stem cells expressing the BCR-ABL gene. The therapeutic concept of BCR-ABL tyrosine kinase inhibition is an effective treatment modality for Ph+ CML as inhibition of BCRABL kinase activity with nilotinib results in apoptosis of Ph+ CML cells.

Nilotinib is an oral TKI which is active against the tyrosine kinase activity of the BCR-ABL protein, the key oncogenic driver in Ph+ CML.

Tasigna is currently indicated for the treatment of:

- Adult and pediatric patients with newly diagnosed Ph+ CML in the chronic phase
- Adult patients with chronic phase and accelerated phase Ph+ CML with resistance or intolerance to prior therapy including imatinib
- Pediatric patients with chronic phase Ph+ CML with resistance or intolerance to prior therapy including imatinib

## CHMP's comment:

The approved posology for paediatric patients in the Tasigna SmPC (4.2.) is:

Posology for Philadelphia chromosome positive CML paediatric patients

Dosing in paediatric patients is individualised and is based on body surface area (mg/m2). The recommended dose of nilotinib is 230 mg/m2 twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). Different strengths of Tasigna hard capsules can be combined to attain the desired dose.

There is no experience with treatment of paediatric patients below 2 years of age. There are no data in newly diagnosed paediatric patients below 10 years of age and limited data in imatinib-resistant or intolerant paediatric patients below 6 years of age.

Furthermore the Tasigna SmPC includes this paragraph in 4.2:

Paediatric population The safety and efficacy of Tasigna in paediatric patients with Philadelphia chromosome positive CML in chronic phase from 2 to less than 18 years of age have been established (see sections 4.8, 5.1 and 5.2). There is no experience in paediatric patients below 2 years of age or in paediatric patients with Philadelphia chromosome positive CML in accelerated phase or blast crisis. There are no data in newly diagnosed paediatric patients below 10 years of age and limited data in imatinib-resistant or intolerant paediatric patients below 6 years of age.

## 2.3.3. Study rationale, study design and study results

The study design and rationale for Study A2409 are summarized in Table 2-1.

<div style=\"page-break-after: always\"></div>

Table 2-1 Summary of study design

<!-- image -->

| Purpose                          | The purpose of this study was to better characterize the long-term safety of nilotinib in patients who were on nilotinib treatment in Novartis-sponsored studies and were benefiting from the treatment as judged by the investigator.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | The purpose of this study was to better characterize the long-term safety of nilotinib in patients who were on nilotinib treatment in Novartis-sponsored studies and were benefiting from the treatment as judged by the investigator.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary objective and endpoint   | Objective To evaluate long-term safety data (SAEs and AEs)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Endpoint Frequency and severity of AEs and SAEs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Secondary objective and endpoint | Objective To evaluate clinical benefit as assessed by the investigator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Endpoint Proportion of patients with clinical benefit as assessed by the investigator at scheduled visits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Study design                     | This was a multi-center, open-label, phase IV study. Patients who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and fulflled all requirements in the parent study could be enrolled into the current roll-over study. Patients returmed to the study center on a quarterly basis (12 weeks ± 1 week) for scheduled visit. AEs (non-serious and serious AEs), clinical benefit assessment by investigator and study medication dispensing information were collected. The original protocol of the current roll-over study was designed to provide continuation of treatment with nilotinib for patients enrolled in nilotinib studies. Therefore, the original protocol did not require AEs (non-serious and serious AEs) to be collected into the clinical databaseandonlyrequiredSAEstobecollectedintheNovartissafetydatabase throughout the study duration. The scheduled visit frequency was annually. However,feedbackfrom health authoritiesstated that all AEs should be collected.To account for this, the protocol was amended in 2016 (Protocol amendment 3, PA 3), with the primary objective changed to assess long-term safety of nilotinib. Consequently, PA 3 started to require all AEs (non-serious and serious AEs) entered into the clinical database, in addition to the continued SAE collection into the Novartis safety database.At the same time, the scheduled visit frequency was increased from annually to quarterly, and the protocol was also amended to require an investigator assessment of clinical benefit for | This was a multi-center, open-label, phase IV study. Patients who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and fulflled all requirements in the parent study could be enrolled into the current roll-over study. Patients returmed to the study center on a quarterly basis (12 weeks ± 1 week) for scheduled visit. AEs (non-serious and serious AEs), clinical benefit assessment by investigator and study medication dispensing information were collected. The original protocol of the current roll-over study was designed to provide continuation of treatment with nilotinib for patients enrolled in nilotinib studies. Therefore, the original protocol did not require AEs (non-serious and serious AEs) to be collected into the clinical databaseandonlyrequiredSAEstobecollectedintheNovartissafetydatabase throughout the study duration. The scheduled visit frequency was annually. However,feedbackfrom health authoritiesstated that all AEs should be collected.To account for this, the protocol was amended in 2016 (Protocol amendment 3, PA 3), with the primary objective changed to assess long-term safety of nilotinib. Consequently, PA 3 started to require all AEs (non-serious and serious AEs) entered into the clinical database, in addition to the continued SAE collection into the Novartis safety database.At the same time, the scheduled visit frequency was increased from annually to quarterly, and the protocol was also amended to require an investigator assessment of clinical benefit for |
| Rationale                        | As mentioned above, the purpose of this study was to better characterize the long-term safety of nilotinib inpatientswho were onnilotinib treatment in Novartis-sponsored studies and were benefiting from the treatment as judged by the investigator. Novartis decided the parent studies which could transfer patients to the roll-over study. All objectives of the parent study had to be reached, and the parent study was to be in the process of being completed andreported. Patients transferred directly from parent studies and commenced treatment with nilotinib as soon as they were consented and met the inclusion criteria of the roll-over protocol. Patients continued to receive nilotinib until one of the following occurred: the patient was no longer benefiting from the treatment, unacceptable toxicity developed, consent was withdrawn, there was non-compliance with the protocol, the investigator felt it was no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | As mentioned above, the purpose of this study was to better characterize the long-term safety of nilotinib inpatientswho were onnilotinib treatment in Novartis-sponsored studies and were benefiting from the treatment as judged by the investigator. Novartis decided the parent studies which could transfer patients to the roll-over study. All objectives of the parent study had to be reached, and the parent study was to be in the process of being completed andreported. Patients transferred directly from parent studies and commenced treatment with nilotinib as soon as they were consented and met the inclusion criteria of the roll-over protocol. Patients continued to receive nilotinib until one of the following occurred: the patient was no longer benefiting from the treatment, unacceptable toxicity developed, consent was withdrawn, there was non-compliance with the protocol, the investigator felt it was no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| Study                    | This study included both male and female, adult and pediatric patients, who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and those who had fulfilled all requirements in the parent study. There was no sample size estimation carried out for this study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Key inclusion criteria   | ● Patients enrolled in a Novartis-sponsored study, receiving nilotinib and those who had fulfilled all requirements in the parent study. · Patients currently benefiting from the treatment with nilotinib, as determined by the investigator. ● Patients who demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. · Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. · Written informed consent obtained prior to enrolling in roll-over study. · If consent cannot be expressed in writing, it was fommally documented and witnessed, ideally via an independent trusted witness.                                                                                                                                                                      |
| Key exclusion criteria   | · Patients were permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason. · Patients who participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy. · Patients who were currently receiving treatment with any medications that had the potential to prolong the QT interval or inducing Torsade de Pointes and the treatment could not be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study .  Pregnant or nursing (lactating) women  Women of child-bearing potential. |
| Study treatments         | The starting dose of nilotinib should be the same as the last dose that was given in the parent study. After this, the dose of nilotinib was based on the investigator's judgement. The maximum dose of nilotinib was 800 mg/day. The regimen was daily, except if total daily dose was 600 mg, it was taken as 300 mg BID, if total daily dose was 800 mg, it was taken as 400 mg BID. The dose for the pediatric patients was calculated based on the body surface area.                                                                                                                                                                                                                                                                                                                                                                                         |
| Key efficacy assessments | Efficacy assessment consisted of clinical benefit of nilotinib treatment as per investigator assessment. The regular collection of investigator attestation of continued clinical benefit only started after PA 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Key safety assessments   | Safety assessments consisted of collecting AEs (non-serious and serious AEs) with their severity, causal relationship to study drug and action taken on study drug, and deaths. All SAEs were collected in the Novartis safety database during the whole study period, AEs (non-serious and serious AEs) were collected in the clinical database after PA 3. Hepatitis B test was required after PA 3.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Data analysis            | The statistical analysis was performed by Novartis personnel according to the planned analysis described in the protocol. SAS version 9.4 or higher was used in all analyses. For complete details, please refer to [Study A2409-CSR-Section 9.7]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## 2.3.3.1. Results

## 2.3.3.1.1. Recruitment

In total, 57 patients were transferred from the CML, ALL, GIST, and KIT mutated melanoma parent studies to this roll-over study. Of the total 57 patients enrolled and treated in the study, 7 patients were below 18 years of age; 4 patients were rolled over from CAMN107A2120 parent study and 3 patients from CAMN107A2203 parent study. Of these 7 patients, four patients completed the study as per the protocol and three patients discontinued the study (one patient due to disease progression and two patients as per physician decision).

<div style=\"page-break-after: always\"></div>

## 2.3.3.1.2.Baseline data

Four pediatric patients (2 to &lt; 12 years) and 3 adolescent patients (12 to &lt; 18 years) were included. Twowerefemaleandfiveweremale.PleaserefertoTable2-2forindividualpatientdetails.

<!-- image -->

| Table 2-2   | Baseline demographics of patients<18 yearsof age   | Baseline demographics of patients<18 yearsof age                        | Baseline demographics of patients<18 yearsof age   | Baseline demographics of patients<18 yearsof age                                                                                                                                                                     |
|-------------|----------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patientcode | Gender                                             | Age category                                                            | Age (years)                                        | Indication                                                                                                                                                                                                           |
|             |                                                    | Pedlatic Pediatric Pediatric Pediatric Adolescent Adolescent Adolescent |                                                    | resistant/intolerant Ph+ CML-CP resistantintolerant Ph+ CML-CP refraclory/relapsedPh+ALL resistantintolerant Ph+ CML-CP resistant/intolerantPh+ CML-CP resistant/intolerant Ph+ CML CP resistantintolerantPh+ CML-CP |

Source: [Study A2409-CSR Listing 16.2.4-1.1; Study A2120-CSR Listing 16.2.4-2.1; Study A2120CSRListing16.2.4-2.3;StudyA2203-CSRListing16.2.1-1.1]

## 2.3.3.1.3.Efficacy results

<!-- image -->

| Country or              | Age / sex   | Assessment date / study date   | Visit            | Investigator confirmation   |
|-------------------------|-------------|--------------------------------|------------------|-----------------------------|
| Subdivision/ subject ID |             |                                |                  |                             |
|                         |             | 03MAR2017/718                  | visit 3          | Yes                         |
|                         |             | 25MAY2018/1166                 | Visit 8          | Yes                         |
|                         |             | 19APR2019/1495                 | End of Treatment | Yes                         |
|                         |             | 18MAY2018/1160                 | Visit 8          | Yes                         |
|                         |             | 03MAY2019/1510                 | End of Treatment | Yes                         |
|                         |             | 12MAY2017/682                  | visit 4          | Yes                         |
|                         |             | 16JUL2018/1112                 | Visit 9          | Yes                         |
|                         |             | 08NOV2018/1227                 | End of Treatment | Yes                         |
|                         |             | 29APR2019/1                    | Enrollment       | Yes                         |
|                         |             | 140CT2019/169                  | Visit 3          | Yes                         |
|                         |             | 27MAR2020/334                  | Visit 5          | Yes                         |
|                         |             | 120CT2020/533                  | Visit 7          | Yes                         |
|                         |             | 03JAN2021/616                  | Visit 8          | Yes                         |
|                         |             | 11JUL2022/1170                 | Visit 14         | Yes                         |
|                         |             | 27FEB2023/1401                 | End of Treatment | Yes                         |

<div style=\"page-break-after: always\"></div>

| 200CT2017/1122   | visit 7          | Yes   |
|------------------|------------------|-------|
| 100CT2018/1477   | Visit 11         | Yes   |
| 05JUL2019/1745   | Visit 14         | Yes   |
| 09JUL2020/2115   | Visit 18         | Yes   |
| 01JUL2021/2472   | Endof Treatment  | Yes   |
| 26MAR2019/1      | Enrollment       | Yes   |
| 24JUN2019/91     | End of Treatment | No    |
| 25JUN2020/1      | Enrollment       | Yes   |
| 26FEB2021/247    | Visit 4          | Yes   |
| 13AUG2021/415    | Visit 6          | Yes   |
| 11NOV2021/505    | Visit 7          | Yes   |
| 28APR2022/673    | Visit 9          | Yes   |
| 09JUN2023/1080   | End of Treatment | Yes   |

The clinical benefit data was collected only afterprotocol amendment 3(PA 3).All the patients of the age below 18 years in the study had at least one clinical benefit assessment on study. All these patientswere stillbenefitingfrom the studytreatment at the endof treatmentvisit,exceptfor one adolescent, female patient who discontinued due to disease progression.

## CHMP's comment:

6 out 7 patients had resistant/intolerant Ph+ CML-CP and 1 patient had refractory/relapsed Ph+ ALL. patient had disease progression three months after enrolment.

It is supported that these limited clinical efficacy data warrants no changes to section 5.1.of the SmPC.

## 2.3.3.1.4.Safety results

AllSAEswerecollectedintheNovartissafetydatabaseduringthewholestudyperiod,however,AEs (non-seriousandseriousAEs)wereonlycollectedintotheclinicaldatabaseafterPA3releasedin 2016，andAEswerenotcollectedsystematicallyuntilthepatientssignedtheICFassociatedwithPA3. Therefore, to present the safety data collected during the study in a comprehensive and transparent way,theSAE datafrom the Novartis safety database was analyzed,in addition to the data collected in the clinical database after PA 3.Based on the safety data collected in the clinical database, all the patients of the age below 18 years experienced AEs. Of note, none of the events were reported as seriousandnoneofthemled topermanentdiscontinuationof thestudydrug.All theeventsreported were of grade 1 or grade 2 severity, except for a grade 3 decreased appetite event in one patient, in one patient each, and increased blood bilirubin and electrocardiogram QT prolonged which occurred in thesamepatient,noneof theeventsweresuspected toberelated to thestudydrugbythe investigator. None of the patients died during the study (Table 2-3).

<div style=\"page-break-after: always\"></div>

Table 2-3 Summary of AEs in patients &lt; 18 years of age

a Eventswhichwerecontinuing at theEoTvisit

<!-- image -->

| Patient code                            | Gender   | Age (years)   | Preferred terms                  | Grade   | Outcome                 |
|-----------------------------------------|----------|---------------|----------------------------------|---------|-------------------------|
|                                         |          |               | Oropharyngeal paln               | 1/2     | Recovered               |
|                                         |          |               | Tracheitis                       | 1       | Recovered               |
|                                         |          |               | Nasopharyngilis                  | 2       | Recovered               |
|                                         |          |               | Tracheobronchillis               | 2       | Recovered               |
|                                         |          |               | Rhinitis                         | 1       | Recovered               |
|                                         |          |               | Ear pain                         | 2       | Recovered               |
|                                         |          |               | Earinfection                     | 2       | Recovered               |
|                                         |          |               | Ligament sprain                  | 2       | Recovered               |
|                                         |          |               | Faligue                          | 2       | Continuinga             |
|                                         |          |               | Poor qualily sleep               | 1       | Recovered               |
|                                         |          |               | Skin depigmentation              | 2       | Recovered               |
|                                         |          |               | Pyrexia                          | 1       | Recovered               |
|                                         |          |               | Lymphadenopathy                  | 1       | Recovered               |
|                                         |          |               | Diarrhoea                        | 1       | Recovered               |
|                                         |          |               | Asthma                           | 2       | Recovered               |
|                                         |          |               | Influenza                        | 2       | Recovered               |
|                                         |          |               | Alopecia                         | 1       | Recovered               |
|                                         |          |               | Pain in exlremity                | 1       | Recovered               |
|                                         |          |               | Dysphonia                        | 1       | Recovered               |
|                                         |          |               | Constipation                     | 2       | Recovered               |
|                                         |          |               | Headache                         | 1       | Recovered               |
|                                         |          |               | Vilamin D decreased              | 1       | Continuinga             |
|                                         |          |               | COVID-19                         | 1       | Recovered               |
|                                         |          |               | Amold-Chiarimalformation         | 1       | Continuing\"             |
|                                         |          |               | Alanineaminolransferaseincreased | 1       | Recovered               |
|                                         |          |               | Blood phosphorus Increased       | 1       | Recovered               |
|                                         |          |               | Eosinophll count increased       | 1       | Recovered               |
|                                         |          |               | Headache                         | 1       | Recovered               |
|                                         |          |               | Oropharyngeal pain               | 1       | Recovered               |
|                                         |          |               | Abdominal pain upper             | 1       | Recovered               |
|                                         |          |               | Pain in exlremity                | 1       | Recovered               |
|                                         |          |               | Growthrelardation                | 2       | Recovered               |
|                                         |          |               | Nasopharyngitis                  | 1       | Recovered               |
|                                         |          |               | Decreased appelite               | 3       | Recovered               |
|                                         |          |               | Growthrelardation                | 2       | Continuinga             |
|                                         |          |               | VitaminD deficiency              | 2       | Recovered               |
|                                         |          |               | Blood billirubin Increased       | 2       | Continuinga Continuinga |
|                                         |          |               | Electrocardlogram QT prolonged   | 1       |                         |
| Source:[StudyA2409CSRListing16.2.7-1.1] |          |               | Rotavirus infection              | 1       | Recovered               |

Based on the Novartis safety database, none of the pediatric patients experienced SAEs.

<div style=\"page-break-after: always\"></div>

## CHMP's comment:

Currently, the Tasigna SmPC includes these paragraphs in 4.8:

## Paediatric population

The safety of nilotinib in paediatric patients (from 2 to &lt;18 years of age) with Philadelphia chromosome positive CML in chronic phase (n=58) has been investigated in one main study over a period of 60 months (see section 5.1). In paediatric patients, the frequency, type and severity of adverse reactions observed have been generally consistent with those observed in adults, with the exception of hyperbilirubinaemia/blood bilirubin increase (Grade 3/4: 10.3%) and transaminase elevation (AST Grade 3/4: 1.7%, ALT Grade 3/4: 12.1%) which were reported at a higher frequency than in adult patients. Bilirubin and hepatic transaminase levels should be monitored during treatment (see sections 4.2 and 4.4).

## Growth retardation in paediatric population

In a study conducted in the CML paediatric population, with a median exposure of 51.9 months in newly diagnosed patients and 59.9 months in imatinib/dasatinib-resistant or imatinib-intolerant Ph+ CML-CP patients, growth deceleration (crossing at least two main percentile lines from baseline) was observed in eight patients: five (8.6%) crossed two main percentile lines from baseline and three (5.2%) crossed three main percentile lines from baseline. Growth retardation related events were reported in 3 patients (5.2%). Close monitoring of growth in paediatric patients under nilotinib treatment is recommended (see section 4.4).

The observed AEs are generally in line with previous reported AEs for Tasigna and are in line with the current SmPC.

It is supported that this submission recommends no changes to the SmPC.

## 2.3.4. Discussion on clinical aspects

Study A2409 was conducted in adult and pediatric patients to characterize the long-term safety of nilotinib in patients who were on nilotinib treatment in Novartis-sponsored studies and were benefiting from the treatment as judged by the investigator. The safety profile of nilotinib in pediatric patient population with Ph+ CML-CP from 2 to less than 18 years of age have been established. There is no experience in pediatric patients below 2 years of age or in pediatric patients with Ph+ CML-AP or blast crisis. Data reported in this study are consistent with the known safety profile of nilotinib in the parent studies and other nilotinib clinical studies. No new safety signal or changes in the frequencies of known risks were identified in the pediatric patient population treated with nilotinib. Based on the results of Study A2409, the favorable benefit-risk profile of nilotinib in pediatric patients with CML remains unchanged.

Based on the results from Study A2409, no changes to the pediatric information of the current Tasigna SmPC are proposed.

## CHMP's comment:

The MAH's conclusion is supported. The benefit-risk profile of nilotinib in its approved indication remains positive and no changes to the SmPC are required.

<div style=\"page-break-after: always\"></div>

## 3. Overall conclusion and recommendation

The MAH's conclusion is supported. The benefit-risk profile of nilotinib in its approved indication remains positive and no changes to the SmPC are required.

<!-- image -->

## Fulfilled:

No regulatory action required.

<div style=\"page-break-after: always\"></div>

## Annex. Line listing of all the studies included in the development program

The studies should be listed by chronological date of completion:

## Clinical studies

Product Name:

Active substance:

| Study title                                                                                                                                                                                                               | Study number   | Date of completion   | Date of submission of final study report   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------------|--------------------------------------------|
| An open label, multi- center nilotinib roll- over protocol for patients who have completed a previous Novartis sponsored nilotinib study and are judged by the investigator to benefit from continued nilotinib treatment | CAMN107A2409   | 7 July 2023          | 15 December 2023                           |